Furthermore, glucose profile was unvaried after adding-on PCSK9-i therapy; at baseline 3 FH subjects were diabetics and no new cases of T2D were detected after adding-on PCSK9-i therapy. Here, PCSK9 is linked to type 2 diabetes mellitus.